Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells

被引:87
作者
Desbarats, J
Duke, RC
Newell, MK [1 ]
机构
[1] Univ Vermont, Coll Med, Dept Med, Div Immunobiol, Burlington, VT 05405 USA
[2] Univ Colorado, Ctr Canc, Shreve Lab Tumor Immunol, Dept Med, Denver, CO 80262 USA
[3] Univ Colorado, Ctr Canc, Shreve Lab Tumor Immunol, Dept Immunol, Denver, CO 80262 USA
关键词
D O I
10.1038/3965
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fas Ligand (FasL) can induce apoptosis of Fas-bearing cells. It is expressed on the cell surface of many tumor cells, immune-privileged tissues and activated lymphocytes. We report here that Fast can itself transduce signals, leading to cell-cycle arrest and cell death in CD4(+) T cells. In vitro, Fast engagement inhibited CD4(+) T-cell proliferation, cell-cycle progression, and IL-2 secretion. In vivo, FasL engagement prevented superantigen-mediated CD4(+), but not CD8(+), T-cell expansion. These findings demonstrate that FasL engagement regulates cell-cycle progression, and show that FasL engagement in vivo has a potent anti-inflammatory effect specific for CD4(+) T cells.
引用
收藏
页码:1377 / 1382
页数:6
相关论文
共 41 条
[31]   CYCLOSPORINE, TOLERANCE, AND AUTOIMMUNITY [J].
PRUDHOMME, GJ ;
VANIER, LE .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1993, 66 (03) :185-192
[32]   Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand [J].
Renno, T ;
Hahne, M ;
Tschopp, J ;
MacDonald, HR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (02) :431-437
[33]   Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain? [J].
Saas, P ;
Walker, PR ;
Hahne, M ;
Quiquerez, AL ;
Schnuriger, V ;
Perrin, G ;
French, L ;
Van Meir, EG ;
deTribolet, N ;
Tschopp, J ;
Dietrich, PY .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1173-1178
[34]   Rejection of Fas ligand-expressing grafts [J].
Seino, K ;
Kayagaki, N ;
Fukao, K ;
Okumura, K ;
Yagita, H .
TRANSPLANTATION PROCEEDINGS, 1997, 29 (1-2) :1092-1093
[35]   Antitumor effect of locally produced CD95 ligand [J].
Seino, KI ;
Kayagaki, N ;
Okumura, K ;
Yagita, H .
NATURE MEDICINE, 1997, 3 (02) :165-170
[36]  
SUDA T, 1995, J IMMUNOL, V154, P3806
[37]   MOLECULAR-CLONING AND EXPRESSION OF THE FAS LIGAND, A NOVEL MEMBER OF THE TUMOR-NECROSIS-FACTOR FAMILY [J].
SUDA, T ;
TAKAHASHI, T ;
GOLSTEIN, P ;
NAGATA, S .
CELL, 1993, 75 (06) :1169-1178
[38]   Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand [J].
Suzuki, I ;
Fink, PJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :123-128
[39]   Fas ligand in human serum [J].
Tanaka, M ;
Suda, T ;
Haze, K ;
Nakamura, N ;
Sato, K ;
Kimura, F ;
Motoyoshi, K ;
Mizuki, M ;
Tagawa, S ;
Ohga, S ;
Hatake, K ;
Drummond, AH ;
Nagata, S .
NATURE MEDICINE, 1996, 2 (03) :317-322
[40]   CTLA-4 ligation blocks CD28-dependent T cell activation [J].
Walunas, TL ;
Bakker, CY ;
Bluestone, JA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06) :2541-2550